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ABSTRACT 
OPTIMIZATION AND APPLICATION OF METABOLOMIC ASSAYS FOR 
ANALYZING DIET-INDUCED AND GUT MICROBIOTA-DERIVED SHORT-
CHAIN FATTY ACIDS IN MICE AND HUMANS 
ROBERT JUENEMANN 
2016 
 Introduction: In recent decades, the obesity epidemic worldwide has prompted 
the need for research targeting disease prevention, treatment, and maintenance. Dietary 
interventions are one of the primary methods to instill positive nutrition habits into one’s 
lifestyle. Thus, resistant starch type 4 (RS4), a prebiotic dietary fiber, has been proposed 
to induce beneficial immunometabolic health outcomes. Currently there is a lack of 
knowledge on the health outcomes of RS4 in adults with metabolic syndrome (MetS). 
Goal: The goal of this research was to optimize a metabolomic assay to quantify fecal 
short chain fatty acids (SCFAs), a byproduct of microbial fermentation in the gut, and to 
apply this assay to health outcomes of RS4 intervention in an adult population with MetS 
as well as genetically induced obese mice. Methods: An assay was optimized to extract 
and derivatize fecal SCFA from human stool samples followed by quantification using 
gas chromatography – mass spectrometry (GC-MS). Retrospective analysis of fecal 
samples from adults including both men (n=4) and women (n=12) with signs of MetS, 
collected at four time points throughout an ad libitum dietary intervention of RS4
2
, were 
processed and quantified. This method was also retrospectively applied to cecum samples 
xiii 
 
of KK.Cg-A
y
/a, genetically induced obese mouse model, to quantify the effects of RS4 
on cecum SCFA concentrations. 16S rRNA sequencing was performed to study the effect 
of RS4 on gut microbial composition. Blood biomarkers, glycemic, and lipid viariables, 
anthropometric measurements, and diet nutrient composition were also studied. Results: 
GC-MS analysis revealed significantly increased SCFAs following RS4 consumption 
including butyrate, propionate, valerate, isovallerate, and hexanoate. 16S-rRNA gene 
sequencing revealed a differential abundance of 71 bacterial operational taxonomic units, 
including the enrichment of three Bacteroides species and one each of Parabacteroides, 
Oscillospira, Blautia, Ruminococcus, Eubacterium, and Christensenella species in the 
RS4 group. RS4-specific associations were found between gut microbial composition and 
SCFA concentrations. Cholesterols, fasting glucose, glycosylated haemoglobin, and 
proinflammatory markers in the blood as well as waist circumference and % body fat 
were lower post intervention in the RS4 group compared with the control group. In 
KK.Cg-A
y
/a mice, butyrate was significantly enriched in RS4 fed mice intestinal tissue. 
Discussion: An optimized method to quantify intestinal and fecal SCFA was created. The 
biological function of RS4 on gut microbiota in inidividuals with MetS was also 
identified. Larger studies are needed to fully understand the mechanistic action of RS4 in 
individuals with metabolic dysfunction for future implications on dietary guidelines.  
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CHAPTER 1. REVIEW OF LITERATURE 
1.1 Nutrigenomics and Health  
In recent years, technology has advanced allowing for the development of many 
different, but related -omics technologies including genetics and disease/condition risk -
genomics, protein expression -proteomics, gene transcription -transcriptomics, and 
metabolism -metabolomics. These –omics technologies in general are a consortium of 
modalities used to investigate the roles, interations, and mechanisms of cells within an 
organism. The creation of these new –omics technologies has led to a dramatic increase 
in the amount of data available to study factors that influence disease susceptibility, 
occurrence, progression and cessation. Dating back to the Greek physician Hippocrates, 
the significant association between an individual’s diet and their health has been cited. 
Bringing together past theories and current technological advancements, interest has 
arisen between bioactive food componants BFCs and its relationship with ones genes.  
Nutrigenomics was first mentioned in 2001 as the new frontier in the science of 
nutrition
3,4
. The term Nutrigenetics was earlier described however, while similar, these 
two disciplines are not interchangeable. Nutrigenomics is the science of how bioactive 
food compounds effect gene expression through epigenetic modifications, miRNA and 
RNA modifications, changes in protein expression and metabolite changes
3,5
. 
Nutrigenetics is the study of genetic variation and dietary response in an individual or 
population
5-7
. The main goals of these sciences include both personalized and 
preventative nutrition
4
.  The future of Nutrigenomics applied to real life has been an 
exciting endeavor however; significant ethical debate around its current application 
exists. A recent review by Pavlidis et al., 2015 outlined the current status of 
2 
 
Nutrigenomics science and its future applications. Its applications on personalized 
nutrition for a subset of responders vs. overall public health brings scrutiny to the overall 
costs and rigor of the newly formed –omics sciences
4
. Bioactive food componants may 
influence gene expression in a variety of mechanisms including via signal transduction 
molecules, their metabolites, or directly
6
. It is widely known that individual’s respond 
differently to dietary consumption, hence the interest in nutrigenomics. Humans are 
predisposed to many different health conditions including obesity, cancers and 
cardiovascular disease based off not only their genetics but also their environment. With 
that being said BFCs may have either a positive or a negative effect on an individual’s 
health. Moving forward, the complexity of this science requires a significant amount of 
research to effectively be applied into today’s dietetic and healthcare settings. 
1.2 Metabolic Syndrome  
The rise in obesity in recent decades has quickly become one of the largest 
burdens on healthcare globally
8
 as it may elevate the risk for development of more 
serious conditions including diabetes mellitus, certain cancers and cardiovascular 
disease
9
, the leading cause of mortality in the US
10
. Obesity in adults can be defined as 
having a BMI at or above 30. In children and adolescents’, obesity is defined as a BMI at 
or above the 95
th
 percentile for their age range and gender. In 2011-2012 it was estimated 
that more than one-third or 34.9% of adults were obese and two-thirds of adults were 
overweight in the US
11
, similar to rates in 2003-2004, however the prevalence of obesity 
has been predicted to rise in coming years
12
. Thompson et al., 2001 found that 
overweight individuals (BMI 25-29) and obese individuals (BMI ≥30) had 37% and 
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105% higher annual prescription costs and 13% and 39% higher primary care costs 
compared to their health counter parts respectively
13
.   
Abdominal obesity, presenting comorbid with some of the most dangerous risk 
factors for developing a heart attack including hypertension, dyslipidemia and insulin 
resistance encompass an even more serious condition, metabolic syndrome. Globally it is 
estimated that 20-25% of the adult population has metabolic syndrome
14
. Between 2003-
2012 in the United States it was estimated that 33% of the adult population and over 50% 
of the population of over 60 years of age had metabolic syndrome causing concern with 
the rapidly growing geriatric population in the US
15
. The International Diabetes 
Federation (IDF) defines metabolic syndrome as follows in Table 1-1. 
Table 1-1: The IDF Definition of Metabolic Syndrome  
Criteria Male Female 
I. Criteria A 
Body Mass Index  >30 kg/m
2
 >30 kg/m
2
 
Waist Circumference  >94 cm >80 cm 
II. Criteria B 
Elevated Triglycerides  ≥150 mg/dL ≥150 mg/dL 
Reduced HDL Cholesterol 
(HDL) 
<40 mg/dL <50 mg/dL 
High Blood Pressure  Systolic > 130 mm Hg Systolic > 130 mm Hg 
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Diastolic >85 mm Hg Diastolic >85 mm Hg 
Elevated Fasting Plasma 
Glucose  
>100 mg/dL >100 mg/dL 
Table 1-1: Criteria used to define MetS based off the (IDF)
14
. An individual is 
considered to have MetS if they present with one item from criteria A and any two 
from criteria B above.  
 Obesity and metabolic syndrome are caused by several environmental, genetic, 
dietary and lifestyle factors including but not limited to, sedentary lifestyle, higher energy 
intake than output, insulin resistance and certain genetic predispositions. Metabolic 
syndrome and its co-morbidities can be treated through lifestyle and/or dietary 
interventions as well as other therapeutics including pharmaceuticals. Despite availability 
of treatment and prevention options, the prevalence of MetS is rising worldwide at an 
alarming rate
10,14
.  
 There are numerous treatment options for metabolic syndrome and its 
comorbidities including medications, dietary interventions/changes, behavioral 
modifications and exercise.  A basic understanding of weight loss reflects the first law of 
thermodynamics which says energy can neither be created nor destroyed; energy intake 
may be neutral (expenditure=consumption), positive (expenditure<consumption), or 
negative (expenditure>consumption). The most obvious influence of energy consumption 
is food consumption, whereas there are three main categories of energy expenditure.  
These categories are: exercise, adaptive thermogenesis and resting metabolic rates
16
. The 
clearest and simplest way to increase energy expenditure is via increased exercise since 
the latter are both mechanisms of survival. Both weight loss medications and reducing 
energy intake are effective interventions in 5-9% weight loss, however weight typically 
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plateaus after six months
17
. A significant struggle with weight loss is long-term success 
and maintenance. Numerous publications identify initial success of weight loss is not 
predictive of long-term success
17,18
. Summerbell et al., 2008 described low-energy and 
low-fat consumption to inverse excess energy intake are not suitable interventions for 
long-term weight loss
19
.  
1.3 Resistant Starch  
In recent decades, growing evidence has been produced supporting the influence 
of diet on the etiology, prevention and treatment of many health conditions. Rapidly 
digested starchy foods such as white pastas, white bread and cakes have long been known 
to influence chronic diseases such as type-2 diabetes mellitus (T2DM) and obesity. 
Normal dietary starch begins its digestion in the mouth as it is broken down by the 
enzyme amylase where it travels further down into the digestive tract and is rapidly 
absorbed as glucose which may potentially result in a hyperglycemic environment in the 
blood. This hyperglycemic condition triggers the release of insulin which cascades into 
tissue-specific intracellular uptake of glucose ultimately leaving a hypoglycemic 
environment in the blood. This cascade of events may result in insulin resistance which 
further may contribute to T2DM and ultimately more serious conditions such as 
metabolic syndrome and cardiovascular disease.  
To combat this rapid glycemic response growing evidence has supported the 
addition of resistant starches (RS) into the diet for disease prevention, maintenance and 
treatment
20,21
. Resistant starches are found both naturally in foods as well as 
mechanically engineered and are classified based on the characteristics that render them 
indigestible (Table 1-2)
22
. Resistant starch is capable of avoiding enzymatic digestion in 
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the mouth and gastral systems however it is susceptible to microbial fermentation thereby 
a slower, more modulated glucose response
20
. Also of interest, is the production of short 
chain fatty acids (SCFA) in the lower gastrointestinal intestinal system (GI) through 
fermentation.
21
 The ability of a RS to be digested by the microbes of our gut renders them 
a prebiotic fiber. A prebiotic fiber is a non-digestible food component which selectively 
serves as a substrate for beneficial microbial species which undergoes  microbial 
fermentation
23
. Resistant starch is a prebiotic friber as it selectively promotes growth of 
beneficial microbes in the gut; however, not all fibers are considered prebiotics, cohersely 
not all prebiotics are resistant starch. A probiotic on the other hand is the healthy, 
commensal bacteria that occupy our gut which through research have contributed to 
beneficial health outcomes
23
.  
Table 1-2: Types of resistant starch
20,22
 
Designation Description Example Reference 
RSI Physically inaccessible 
starch 
Coarsely ground or 
whole-kernel grains 
Englyst et al., 
1992
22
 
RSII Granular starch with the 
B- or C- polymorph 
High amylose maize 
starch, raw potato, 
raw banana 
Englyst et al., 
1992
22
 
RSIII Retrograded Starch Cooked and cooled 
starchy foods 
Woo et al., 
2002
24
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RSIV Chemically modified 
starch 
Crosslinked starch 
and octenyl succinate 
starch 
Han, BeMiller, 
2007
25
 
RSV Amyloid-lipid complex Stearic acid-
complexed high-
amylose starch 
Seneviratne, 
Biliaderis, 
1991
26
 
1.4 Microbiome 
The etiopathology of obesity and metabolic syndrome have been of interest 
worldwide due to their complexity and rapidly increased occurrence. More recently, the 
relationship between the microbiome and health has been of growing interest. The 
microbiome encompasses all of the microbes that occupy our body space. It is estimated 
that these microbes make up over ten times higher the number of cells in the body, with 
the majority residing in the large intestine. The gut microbiome plays a crucial role in 
nutritional sciences as it increases the metabolic potential of the human host thereby 
digesting food components we would not otherwise be able to.   
The composition of the gut microbiome is influenced by many factors including 
age, diet, disease, medications and host genetics
27,28
. The gut microbiome is primarily 
made up of six bacterial phyla: Firmicutes, Bacteroidetes, Proteobacteria, Actinobacteria, 
Fusobacteria, and Verrucomicrobia. Though complex, research has produced common 
trends associated with certain disease states including obesity, cancers and T2DM.  Gut 
microbiome plays a crucial role in interacting with our mucosal immune system. The 
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interaction between the human host, gut microbiome and diet is complex as noted in 
Figure 1-1. It has been found that microbial fermentation may increase energy production 
from the diet, contribute to low-grade inflammation and influence fatty acid tissue 
composition
27
. Despite the rapid increase of publications regarding the gut microbiome 
and obesity, there is a significant variation in microbial composition from person to 
person however, trends suggest a healthy and more disease-like state. A significant 
number of studies describe an obese-like microbiome as having an increased Firmicutes: 
Bacteriodetes ratio
27,29,30
.  
 
Figure 1-1: Relationship of the gut microbiome, diet, and human host
1
.  
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The addition of RS to the diet has been shown to have beneficial influences on the 
gut microbiome and immunological functions in both mouse models and human 
interventions. RS in the diet has been shown to increase the abundance of beneficial 
microbes including Bifidobacterium adolescentis, Ruminococcus bromi, Eubacterium 
rectale, and Parabacterium distasonis as well as improving the Firmicutes: 
Bacteriodetes
30,31
. It is important to note that the results previously mentioned resulted 
from the consumption of different types of RS concluding that microbial growth and 
colonization are substrate dependent
32
.  
1.5 Hutterite Brethren Population of South Dakota  
South Dakota is home to a large population of Hutterites, one of the oldest and 
most successful Anabaptist Brethren societies, the Hutterites. Their culture dates back to 
1528 from South Tyrol, once part of Austria. Their population has endured significant 
hardship however, their population has expanded to over 40,000 individuals across 
Canada and the USA, primarily in the Midwestern states including North Dakota, South 
Dakota and Canada
33
. Their communal lifestyle has led to a genetically isolated 
population resulting in a founder effect resulting from the genetic flow from the original 
89 community founders which can be associated to the Mendelian disorders present 
within this community
33,34
. The inclusion of the Hutterite population in genetic studies 
has increased significantly in recent decades positively impacting the ability to identify 
specific genes related to disorders that are unique to this population. Their inclusion as a 
study population provides a significant opportunity to avoid potential genetic factors due 
to their genetic isolation. 
10 
 
In the context of nutrition and gut microbiome research, the Hutterites restrict the 
potential environmental factors that may impact study results. Their communal lifestyle 
within their colonies involves centralized preparation and consumption of their three 
main meals. This communal dining limits the potential variation amongst their diet. A 
major cause of variation is seasonal availability of fruits and vegetables (fresh fruits and 
vegetables being available for consumption in summer and fall months, preserved, 
canned, or frozen fruits and vegetables in winter and spring months). This seasonal 
variability has lead to the microbial shifts across seasons including the abundance of 
particular taxa including Firmicutes and Bacteroidetes as well as overall microbial 
diversity
35
.  
1.6 Intervention Study  
In order to further understand the effects of RS4, Nichenametla et al., 2014 
performed a double-blind, placebo-controlled, cluster crossover intervention in two 
Eastern South Dakota Hutterite colonies
2
. The two Hutterite colonies (n=86) were 
randomized to alternatively receive either the test flour or control flour (Table 1-3) in two 
consecutive 12-week treatment periods with an appropriate two-week washout period 
(control flour consumed) in between as shown in Figure 1-2. Preexisting colony flours 
were removed and replaced with test flours which were fed ad libitum in a domestic, free-
living, communal environment. Participants in this study were ≥18 years old and 
provided written informed consent to participate. Exclusion criteria for this study include 
lactating or pregnant females, long-term antibiotic therapy, immune compromised, cancer 
and other chronic conditions inhibiting one’s ability to provide informed consent and 
abide by study protocol. 
11 
 
 
 
Figure 1-2: Crossover design timeline of 26 week long study period. Flours 
consumed in two 12 week treatment periods were randomized by colony following 
initial baseline (BL). The two treatments were divided by a two week washout 
period (WO) followed by consumption of the opposite treatment flour. Arrows 
depict time of data and specimen collection.  
Table 1-3: Nutrient composition of treatment flours 
Nutrient (g/100g) Control Flour  RS4 Flour  
Water 13.4 12.5 
Protein 11.0 7.9 
Carbohydrates 73.5 77.8 
Total fat 1.7 1.3 
Saturated fat 0.2 0.2 
Monounsaturated fat 0.1 0.1 
12 
 
.  
 
 
 
 
 
 
 
  
The results of this study show that RS4 consumption improved dyslipidemia by 
significantly decreasing mean total cholesterol, lower non-HDL cholesterol and HDL 
cholesterol in individuals with metabolic syndrome. In conclusion the aims of this thesis 
was to mechanistically explore the effects of RS4 on individuals with metabolic 
syndrome and the gut microbiome.  
 Initially collaboration was sought out within various departments at SDSU to 
investigate fecal SCFA however no optimized method was found. Protocols were found 
for volatile fatty acids but of larger molecular structure and concentration. Due to the low 
concentration of SCFAs anticipated in the potential samples, their high volatility, and low 
molecular weights, these GC-MS machines were incapable of reaching the lower 
detection limit desired. Outside collaboration was sought out to local laboratories. 
Polyunsaturated fat 0.7 0.6 
Trans-fat 0.0 0.0 
Fiber (RS4) 2.4 (0.0) 25.7 (24.0) 
Sugars 0.3 0.2 
Ash 0.5 0.6 
Calcium (mg/100g) 24.0 50.4 
Sodium (mg/100g) 2.0 91.4 
Vitamin C (mg/100g) 0.0 0.4 
Calories (kcal) 361.0 266.8 
13 
 
Outside collaboration attempts found high cost, inadequate amount of sample, and low 
detection ranges. At this point the research need within SDSU for current and future 
studies to optimize a method for SCFA extraction and analysis via GC-MS was 
identified. Two professors within SDSU’s Pharmacy and Chemistry with GC-MS 
capacity initially assisted with previously published protocol replication (outcomes of 
protocol replication in section 2.4). Unfortunately, retirement, machine use, and lack of 
laboratory assistance/support limited the success of these collaborations. Since recourses 
at SDSU were exhausted, Dr. Dey sought out collaboration with Dr. Ali Reza Fardin-Kia 
with this US Food and Drug Administration which ultimately lead to the successful 
protocol developement.  
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CHAPTER 2. OPTIMIZATION OF A METABOLOMIC ASSAY TO ANALYZE 
SHORT CHAIN FATTY ACIDS IN HUMAN FECES 
2.1 Introduction 
Upon reaching the lower GI tract, prebiotic fibers such as RS, undergo microbial 
fermentation which produces SCFAs. SCFAs of particular interest include acetate, 
propionate, and butyrate which have numerous physiological impacts on the body such as 
inducing satiety, hepatic lipogenesis, fat deposition, and thermogenesis
36,37
.  Short-chain 
fatty acid production directly correlates with the type of substrate in the diet and 
microbial availability in the gut. The majority of SCFA produced are absorbed by the 
intestinal epithelium and used in other metabolic processes or are used by other intestinal 
microbiota. The study of the gut microbiota and fecal SCFA production is controversial 
as only 5-10 % of SCFA produced are excreted in feces (the primary method of study)
38
 
however this is the most practical method of SCFA study in clinical trials. It has been 
estimated that SCFA production can account for 5-15% of daily human caloric intake
39
. 
The molar ratio of SCFA is estimated 60:20:20, acetate, propionate and butyrate 
respectively
38,40
. 
Butyrate is of particular interest in research as it has been found to have many 
effects on energy metabolism, inflammation, host immunity and cancer. There are two 
proposed mechanisms of butyrate production 1) Butyrate kinase and 2) Butyryl-
CoA:acetate-CoA transferase
41
. Commonly cited butyrogenic bacteria include: 
Eubacterium rectale, Eubacterium ramulus, Roseburia cecicola and members of 
Clostridium cluster IV
42
. It is well known that butyrate is the main energy source for 
colonocytes once absorbed. Inflammation is commonly associated with both obesity and 
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cancer.  Butyrate plays a crucial role in inflammatory response in the gut by inhibiting 
pro-inflammatory markers such as IL-6 and inhibiting NF-kBactivation as well as 
upregulating PPARγ expression
43,44
.  
Propionate and acetate play fundamental roles with the liver where they both may 
be metabolized, acetate forming acetyl-CoA and contribute to gluconeogenesis. 
Propionate has been shown to increase HDL cholesterol production in humans as well as 
reduce blood cholesterol in animal models
45
. Acetate and propionate have also been 
shown to play a role in adipocyte formation through interaction with G-protein coupled 
receptors and also influence adipokine release which may induce satiety
46
. Acetate has 
been noted to induce satiety signaling through hypothalamic reaction after 
administration
47
.  
 Relating this to obesity and metabolic syndrome, the addition of RS to the diet 
reduces the energy density by which intestinal gluconeogenesis is initiated and satiety is 
induced through activation of these SCFA
48
. The complex relationship between the gut 
microbiome, SCFA and obesity has yet to be fully understood. In today’s western diet the 
amount of fiber in the diet is limited, drawing concern over health outcomes/trends, 
especially the obesity epidemic. On average in the US the daily fiber intake is 16 grams 
for individuals 2 and older
49
. The dietary reference intake for total fiber for adult male 
and females is between 21-38 grams per day
50
. The addition of fiber into the diet has 
been of growing interest for health organizations in recent decades due to the increasing 
evidence of health promotion via SCFA production. While there is no recommended 
dietary reference intake values for RS consumption in the US, it is estimated that the 
average daily intake is 3-8 grams per day in the US
51
.  
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The increased biological relevance of these compounds has increased the need to 
develop rapid and accurate detection platforms. Detecting SCFA in fecal samples is 
particularly difficult due to the complex matrices into which they reside
52
.  There are 
several pretreatment protocols available in which the SCFAs are extracted using an 
aqueous or organic solvent and often times followed by a derivatization reaction to 
increase the volatility and compatibility with the GC-MS analysis. In section 2.4 two 
methods are described which were attempted one with a simple extraction and one with 
an additional derivatization reaction.  
The objectives of this project were 1) to develop and optimize a protocol to analyze 
SCFA in human fecal samples and 2) to investigate the impact of RS4 on fecal short 
chain fatty acid (SCFA) concentrations in adults with metabolic syndrome.   
2.2 Materials and Methods 
2.2.1 Participants 
Participants in this study included a subset of the parent cohort (section 1.6) 
consisting of 20 individuals who originally participated in a dietary intervention with 
RS4
2
. The parent trial is registered in clinicaltrials.gov (NCT01887964). From 40 
participants who had signs of metabolic syndrome at baseline, 26 participants submitted 
stool samples at all four data collection time points. Out of 26, 20 participants (10 from 
each of the two colonies) were included in the current investigation as their fecal samples 
were adequate to carry out both sequencing and short chain fatty acid (SCFA) analyses. 
Exclusion criteria included pregnancy, lactation, long-term antibiotic therapy, immune 
compromised state, cancer, and other conditions that would affect the ability to provide 
informed consent or comply with the protocol. 
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 2.2.2 Sample preparation.  
Performed at South Dakota State University, 1.5mg/mL internal standard (IS, 2-
ethylbutyric acid, Thermo Fisher Scientific, Waltham, MA) was prepared in 1-butanol 
(Thermo Fisher Scientific, Waltham, MA). Exact weight of IS was recorded. 800-
1000mg (±0.1mg) fecal sample was homogenized and added to a 30mL glass tube with a 
Teflon cap (Thermo Fisher Scientific, Waltham, MA) containing 1mL IS.  500µL hexane 
(Thermo Fisher Scientific, Waltham, MA) and 2mL of the appropriate catalyst were then 
added with one minute of vortexing between each addition. Boron trifluoride 1-butanol 
(BF3-B, Sigma Aldrich, St. Louis, Missouri) and hydrogen chloride 1-butanol (HCl-B, 
Sigma Aldrich, St. Louis, Missouri) were used to create butyl- esters for SCFA detection. 
Boron trifluoride 1-methanol (BF3-M) was used to create methyl- esters for MCFA 
detection. Samples were then sonicated for five minutes at 40 KHz, purged with nitrogen 
or helium gas (Matheson, Sioux Falls, SD), and placed in a water bath (90-100
oC
) for 20 
minutes. Once cooled to room temperature, 15mL of water and an additional 1.5mL of 
hexane were added to the samples and centrifuged at 3,000g*min
-1
 for two minutes. The 
organic layer (top) was then transferred into a sampling vial (Agilent Technologies, 
Wilmington, DE) with a final addition of ~100mg anhydrous sodium sulfate (Thermo 
Fisher Scientific, Waltham, MA).  Fecal SCFA extracts were stored at -20
o
C. A 
schematic view of the protocol is indicated in Figure 2-1. 
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Figure 2-1: Optimization of a metabolomic assay to analyze SCFA in human feces. 
 
2.2.3 Gas chromatography- mass spectrometry analysis.  
Performed at the US Food and Drug Administration, (College Park, MD) fatty 
acid analysis was executed using GC-MS 5977A (Agilent Technologies, Wilmington, 
DE). Analytes were run on a HP-5MS UI capillary column (30 m x 0.25mm, 0.2 μm 
thickness, Agilent, Wilmington, DE). Sample volume of 1µL was injected in the split 
mode (1:10).  The carrier gas in this system was hydrogen with a constant flow rate of 
2mL/min.  Oven temperature ramp was as follows: 55
oC
 for 4 minutes, then to 120
 oC
  at 5
 
oC
 /min, then to 220
 oC
  at 20
 oC
 /min for 10 minutes. Selective mass detector was utilized 
in the “single ion monitoring and scan” (SIM/Scan) mode with its source being 
maintained at 150
 oC  
and the electron energy set to 70eV. A schematic view of the GC-
MS protocol is shown in Figure 2-2. 
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Figure 2-2: GC-MS method for SCFA analysis. 1. Hydrogen used as carrier gas at 
1.9mL/min. 2.  Injection volume 1uL in split mode (1:10). 3. Initial elution 
temperature was 55
o
C for 4 min, then 5
o
C/min to 120
o
C and then 20
o
C/min to 220
o
C 
for 10 min. 4. Mass detector operated in SIM/Scan mode. 5. Ion source 150
o
C. 6. 
Electron energy 70eV. 
 
2.2.4 Statistical analysis  
Descriptive statistics were performed on demographic information. Data was 
analyzed comparing end-points for outcome variables in CF and RS4 groups, or pre- and 
post-intervention measures. For pre- and post-intervention comparisons paired t-test 
(Wilcoxon signed-rank test for non-normal data) was used, while student’s t-test (Mann-
Whitney signed-rank test for non-normal data) was used to compare the two different diet 
groups. Where necessary, data was logarithmically transformed to achieve normality. A p 
value of 0.05 or less was considered significant, while p value of 0.05 to 0.09 was 
considered trend or approaching significance. 
2.3 Results and discussion.  
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 Descriptive characteristics of this study cohort are summarized in Table 2-1. Of 
the original cohort, at baseline, 40 individuals met the IDF definition of MetS
14
. 26 
participants of these subjects submitted stool samples at all four visits. Out of these 26 
individuals (ages 32-77), 20 had fecal microbial DNA at sufficient concentration for next 
generation sequencing (NGS). These 20 individuals were from two colonies, ten from 
each colony, two being men and eight being women. Medication for comorbid conditions 
and prophylaxis are reported in Table 2-1 below.  
Table 2-1: Baseline characteristics of 20 participants. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Criteria n 
Age (years)  
<50 5 
≥50 15 
  
BMI  
<30 5 
≥30 15 
  
Gender  
Male 8 
Female 12 
  
Medication for  
No medication 8 
Type 2 diabetes 4 
Heart diseases 2 
Blood pressure 11 
Fibre supplement 2 
Probiotic 
supplement 
1 
Digestive support 3 
Cholesterol 
lowering 
5 
n: number of individuals.
53
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Figure 2-3: Representative chromatogram showing the overlay of retention times of 
butyl esters of SCFA fragment from standard and biological sample. Butyl esters of 
acetic acid (1), propionic acid (2), iso-butyric acid (3), butyric acid (4), iso-valeric 
acid (5), valeric acid (6), internal standard (7), and hexanoic acid (8) represents the 
di-butyl ether as a side product of butylation that did not co-elute with the sample 
analytes. 
A representative chromatogram of the SCFA butyl esters is shown in Figure 2-1. 
The total SCFAs were increased after RS4 intervention as expected (Figure 2-2). Acetate 
made up the majority of SCFA present at 60% of the total SCFAs before and after both 
CF and RS4 interventions (data unshown).  Propionate (50.2%), butyrate (69.5%), 
valerate (44.1%), isovalerate (20.3) and hexanoate (19.2%) were significantly increased 
post RS4 intervention from baseline as expected. Interestingly a 25.6% decrease in 
isobutyrate was observed following RS4 diet.  
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Figure 2-4: Effects of RS4 on fecal SCFAs abundance before and after RS4 
intervention (* p ≤ 0.05,)
53
 
2.4 Supplementary protocols attempted and Results.  
 Prior to optimizing the methods in section 2.2.2 and 2.2.3 we attempted to 
replicate two previously published methods to extract and analyze SCFA Garcia-Villalba 
et al., 2012
52
 and Zheng et al., 2013
54
.  The working protocol according to Zheng et al., 
2013
54
 is briefly as follows: 50mg (25-150 is acceptable) was weighed in a 30mL test 
tube. 1,000µL of 0.005 M aqueous NaOH was added to the fecal sample and 
homogenized for ten minutes, sonicated for ten minutes, and finally centrifuged at 
13,200rpm for 20 minutes. A 500µL aliquot of supernatant fecal water was transferred 
into a 10mL glass tube where10µL of internal standard (200ug/ml propionic2,2-D2), 
250µL of water are added. Sample derivatization occurred by adding 500µL of 
propanol/pyridine (3:2), and 100µL of Propyl Chloroformate (PCF) to the 10 mL glass 
tube with prepared sample. The sample was then vortexed for ten seconds and sonicated 
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for one minute. 300µL of hexane was added into the glass tube, vortexed for one minute, 
let stand for ten minutes and centrifuged at 2,000rpm for five minutes. 200µL of the 
upper hexane layer was transferred to a vial as the first extraction. Another 200µL of 
hexane was added into the glass tube, vortexed for one minute, let stand for ten minutes 
and centrifuged at 2,000 rpm for five minutes. An additional 200µL of upper hexane 
layer was transferred to the vial with the first extraction in it followed by adding a small 
amount of anhydrous sodium sulfate for water absorption and vortexed for 15 seconds. 
 Standards of each SCFA were prepared and initially ran per protocol on the GC-
MS which resulted in no visible peaks on the chromatogram. The heating scheme of the 
GC-MS analysis was then altered by gradually raising the temperatures however the 
temperature limit was eventually reached. The flow rate was increased and peak began to 
appear, however they exhibited “tailing” which exhibits a wide tail-end of the peak 
typically caused by a dirty column. This led to questioning the capabilities of the column 
that was used regarding polarity, solute, or solvent conflict however the DB-5ms (5% 
phenyl) methyl polysiloxane should behave the same as the column indicated in the 
protocol. The program was run several times with only hexane in an attempt to clean the 
potentially dirty column which eventually eluted cleaner peaks. Figure 2-3 shows an 
example chromatogram with acetic acid laid on top of the blank. There are a couple of 
early peaks (< 4.00 minutes) and then a group of peaks at approximately 18 minutes. Per 
protocol acetic acid should elute < 3.00 minutes concluding that the peaks present are 
false. Figure 2-4 shows propionic acid laid on top of the blank. The only peaks that differ 
between blank and sample are the two peaks shown at 18 min. Again, the reference peaks 
per protocol eluted < 5.00 minutes concluding that these peaks were also false. Figure 2-5 
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shows butyric acid laid upon the blank. The only two peaks that deviate from the blank 
appear very early, before the expected acetic acid and propionic acid which also conclude 
these peaks as false. Through further adjusting of the temperature scheme, peaks were 
identified for acetate, propionate, and butyrate standards all of which were at the same 
concentration by calculation however appeared different levels on the chromatogram, 
pipetting technique, multiple pipettes, and again column cleanliness were investigated. 
Peaks began to show at 2.00 minutes (acetate), 2.60 minutes (propionate), and 4.20 
minutes (butyrate) however these peaks exhibited fronting so further concern grew 
regarding a more polar column, ramp speed and gas flow. The GC-MS was also changed 
from split to splitless mode which exhibited no change in chromatogram. Further 
adjustments with this system resulted in ultimately losing the peaks on the 
chromatogram. 
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Figure 2-5: Acetic acid vs. blank chromatogram 
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Figure 2-6: Propionic acid vs. blank chromatogram 
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Figure 2-7: Butyric acid vs. blank chromatogram 
 At this point with concern over the success of the derivatization reaction so a 
second protocol that was simply an extraction, void of any derivatization was attempted. 
The working protocol used for Garcia-Villalba et al., 2012
52
 is as follows: fecal samples 
were weighed to the nearest 100mg in a 30mL glass tube. The samples were suspended in 
1mL of water with 0.5% phosphoric acid per 0.1g of sample. Samples were then vortexed 
for two minutes and centrifuged at 17,949xg for ten minutes. The supernatant was then 
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pulled off and the SCFAs were extracted with 1mL ethyl acetate per 1mL of supernatant. 
Samples were then let stand for two minutes and vortexed followed by another 
centrifugation at 17,949xg for ten minutes. 600µL of supernatant was then aliquoted into 
a sampling vial where the internal standard propionic2,2-D2 was added at 500µM. The 
samples were stored at -20
o
C until use. Upon GC-MS analysis, no peaks eluted onto the 
chromatograph.  
2.5 Limitations and Future Research.  
The conclusion of this chapter resulted in an optimized method for fecal SCFA 
extraction, derivatization and GC-MS analysis. As expected we observed increased 
SCFA following RS diet
31,55
. The health consequences of butyrate and propionate, both 
of which were increased following RS4 consumption are noted above. Valerate is also of 
interest as it and propionate have been found to influence insulin-sensitivity in 
adipocytes
55
.  Interestingly isovalerate (commonly associated with protein creation) was 
increased following RS4 consumption; this finding is unique as prior research found a 
decrease in isovalerate following RS consumption
56
. Further research is needed to 
understand the full biological effect of RS4 on SCFA production via microbial 
fermentation in the gut.  
The optimization of this protocol leaves a resource for future investigators and 
elsewhere (we have demonstrated usefulness of this protocol for human subject research 
through our publication) to study fecal SCFA levels. The derivatization method in the 
protocol above produces –butyl esters which are of optimum size to study SCFA
57
. Of 
important note this method was also attempted using BF3-M which resulted in the 
formation –methyl esters which are ideal to analyze medium and long chain fatty acids. 
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Experimentation with BF3-M ran short due to lack of time. To move forward an optimal 
internal standard (IS) needs to be determined to quantify these fatty acids in samples. An 
optimal IS would fall into the same range on the chromatogram that MCFAs would elute. 
It is also important to investigate the expected fecal concentrations, elusion times, and 
machine capabilities. 
A limitation to this method is that once analyzed via GC-MS, roughly a quarter of 
the duplicate samples had concentrations that were not closely related. When the samples 
are being homogenized it is difficult to ensure a homogenous slurry as the consistency 
and content of the sample is different throughout. Rotating the homogenizer in a circular 
motion broke down the frozen sample more rapidly than direct pressure to the sample.  
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CHAPTER 3. APPLICATIONS IN MATABOLOMICS RESEARCH  
3.1 Introduction 
 The obesity epidemic over the past several decades has significantly impacted the 
need for effective prevention, treatment and maintenance strategies for obesity and its 
comorbidities. One mechanism to impact MetS is dietary intervention. In a previous 
report, Nichenametla et al., 2014 found that an RS4 diet lead to 7.2% lower mean 
cholesterol (TC), 5.5% lower non-HDL cholesterol and a 12.8% reduction in HDL in 
individuals with MetS
52
.  Many studies report the benefit of incorporating fiber and other 
nutrient dense food items to the diet to combat MetS
21,58
.  
 Diet has been found to variably impact the composition of the microbiome in both 
animal models and human dietary interventions. Physiological response and level of 
change varied by the individual however are attributable to type of RS consumption
32
. 
Response of the microbiome is also substrate specific. RS4 consumption increased 
Bacteroidetes, Actinobacteria, Bifidobacterium adolescentis, and, Parabacterium 
distasonis while decreasing Firmicutes in healthy individuals, whereas RS2 increased 
Ruminococcus bromii and Eubacterium rectale
32
. This study raises the question if RS4 
will improve the Firmicutes:Bacteroidetes ratio in individuals with MetS as it did in 
healthy individuals. In healthy adults RS2 was also found to increase Bifidobacterium 
adolescentis and Ruminococcus bromii which supports the findings above
31
.  
 Obesity and MetS are both associated with inflammatory conditions throughout 
the body. IL-6 and TNF-α are proinflammatory cytokines secreted by adipose tissue that 
are commonly linked to obesity and insulin resistance
59,60
. RS2 consumption in 
individuals with T2DM was found to significantly decrease TNF-α but had no effect on 
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systemic IL-6 or adiponectin
61
.  Gargari et al., 2015 found RS2 consumption significantly 
decreased TNF-α, HbA1C and triglycerides while also increasing HDL-cholesterol
62
. 
Adoponectin is a protein derived from adipocytes that is negatively associated with waist 
circumference and MetS
63
. In diabetic rats RS consumption increased the concentration 
of circulating adiponectin
64
. In mice, cecum samples are commonly used to investigate 
SCFA production as this is where SCFAs are most abundant. Mice research gives 
investigators a base for human intervention studies.  
The objective of this project were to investigate the immunometabolic effects of 
RS4 and apply the method from Chapter 2 to metabolomics research. The specific aims 
of this project were: 1) to investigate how RS4 modulates the gut microbiome in 
individuals with MetS; 2) to determine if RS4 is altering lipid, glucose and 
anthropometric measurements in individuals with MetS; 3) to investigate if there is an 
association between changes in gut microbiome and lipid, glucose, anthropometrics and 
fecal SCFA levels post-RS4 intervention; and, 4) to investigate the effect of RS4 diet on 
cecum concentrations of SCFAs in mice.  
3.2 Materials and Methods  
The methods listed directly coincide with our already published data by Liu et al., 2016
65
 
(3.2.1) and Nichenametla et al., 2014
2
 and Upadhyaya et al., 2016
53
 (3.2.2-3.2.7).  
 3.2.1 Mice and Participants  
 Mice data used in this study were a part of another study
65
 whose objective was to 
investigate the effects of RS4 in a genetically induced obese model of mice, KK.Cg-A
y
/a 
(Jackson Laboratories, Bar Harbor, ME). In brief, Six-week old mice were randomly 
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grouped for feeding with RS4 and standard (control) diets. During the first three weeks, 
mice were allowed to acclimatize and fed standard rodent chow, LabDiet
®
 5001 (Purina, 
Saint Louis, MO). Animals were then switched to experimental diets formulated based on 
AIN 93 either with (23.5% - RS4 diet) or without (0% - regular/control diet) RS4. 
Animals were fed experimental diets for 13 weeks followed by termination (CO2 
asphyxiation).  
For human data, participants are the same cohort as indicated in section 2.2.1. 
3.2.2 Fecal Genomic DNA extraction  
 Genomic stool DNA was extracted from human fecal samples using the QIAamp 
DNA Stool Mini Kit (QIAGEN Inc., Valencia, CA) according to the manufacturer’s 
instructions. Initially, 0.3-0.5g of each fecal sample was weighed into an appropriately 
labeled 15mL tube. ASL buffer was then added to the specimen at 10mL/g feces 
followed by sufficient vortexing to achieve homogenous distribution of the sample. The 
sample was then placed in a water bath at 95
o
C for three minutes and subsequently 
vortexed. Next, the samples were centrifuged for five minutes at 1500xg followed 
removing a 1.6mL aliquot into a new 2mL tube. The samples were then heated at 95
o
C 
for five minutes, vortexed for 15 seconds, and subsequently centrifuged for one minute at 
20,000xg. 1.2mL of supernatant was then transferred into a new 2mL tube containing 
InhibitEX and vortexed immediately until complete suspension of the tablet. The 
suspension was then centrifuged down for three minutes at 20,000xg. All supernatant was 
removed and again centrifuged down for three minutes at 20,000xg. 200µL of 
supernatant was transferred to a new 2mL tube following the addition of 15µL of 
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proteinase K and 200µL of AL buffer. Samples were vortexed for 15 seconds and 
incubated at 70
o
C for ten minutes followed by an additional 2,000xg centrifugation for 
one minute. 200µL of absolute ethanol was then added, vortexed, and centrifuged for one 
minute at 2,000xg. The lysate was then transferred into a new spin column and 
centrifuged at 20,000xg for one minute. The spin column was then transferred into a new 
collection tube and 500µL of AW1 buffer was added. The sample was then centrifuged at 
20,000xg for one minute. The transfer column was again transferred to a new collection 
tube, 500µL of AW2 buffer was added, followed by a three minute centrifugation at 
20,000xg. The column was then transferred into a new 1.5mL tube where 200µL of AE 
buffer was added onto the column membrane. The sample was then incubated for three 
minutes at room temperature and subsequently centrifuged for one minute at 15,000xg. 
The concluding DNA sample was then kept on ice and quantified using the NanoDrop 
system (NanoDrop Technologies, Wilmington, DE) and/or the quantified via the Qubit® 
Quant-iT dsDNA Broad-Range Kit (Invitrogen, Life Technologies, Grand Island, NY). 
 3.2.3 Gut microbiome and community structure analysis 
Sample DNAs were sent to Second Genome (South San Francisco, CA) for 
metagenome sequencing and operational taxonomic unit (OTU) identification. Briefly, 
samples were enriched for bacterial 16S V4 rDNA region, DNA was amplified utilizing 
fusion primer designed against the Illumina (San Diego, CA) flow cell adapters and 
indexing barcodes. Each sample was PCR-amplified with two differently bar coded V4 
fusion primers. For each sample, amplified products were concentrated using a solid-
phase reversible immobilization method for the purification of PCR products and 
quantified by electrophoresis using an Agilent 2100 Bioanalyzer® (Agilent 
32 
 
Technologies, Santa Clara, CA). Sequencing was carried out using Illumina MiSeq 
platform following standard protocols for 250 cycles with custom primers designed for 
paired-end sequencing. Using Quantitative Insights Into Microbial Ecology or QIIME 5 
and generated custom scripts (Second Genome), sequences were quality-checked and 
demultiplexed to determine exact matches to the supplied DNA barcodes. Resulting 
sequences were then searched against the Greengenes reference database of 16S rRNA 
gene sequences, clustered at 97% by uclust (closed reference OTU picking). The longest 
sequence from each OTU was then assigned taxonomic classification via Mothur's 
Bayesian classifier, trained against the Greengenes database clustered at 98%. For 
unidentified Greengenes OTUs, we cross referenced with closest hits from NCBI 16S 
rRNA database with query cover (>90%), identity (>87%), and E value (<0.01). 
3.2.4 Anthropometric measurements (Data previously collected and  
retrospectively analyzed here)  
Height and waist circumference were obtained, to the nearest 0.5cm by 
stadiometer and Gulick tape respectively. Weight was determined by electronic scale 
(Seca Gmbh & Co., Hamburg Germany) to the nearest 0.1kg. Dual-energy x-ray 
absorptiometry (DXA) (Hologic QDR Discovery A, Waltham, MA) was used to analyze 
body composition at visit 1, 2 and visit 4. Digital sphygmomanometers were used to 
measure blood pressure.  
3.2.5 Blood glycemic and lipid variables (Data previously collected and  
retrospectively analyzed here)  
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Overnight fasting blood was collected at each visit (Figure 2-1) by venipuncture. 
10mL of peripheral blood was collected in heparin-coated Vacutainer tubes (BD 
Biosciences, Franklin Lakes, NJ). Immediately following collection 40µL of blood was 
analyzed using the Cholostech LDX point-of-care analyzer (Alere Inc, Waltham, MA) 
with lipid profile and glucose cassettes (Lipid Profile GLU, Alere Inc, Waltham, MA) 
according to the manufacturer’s instructions to analyze blood glucose, total cholesterol 
(TC), low-density lipoprotein cholesterol (LDL), high0density lipoprotein cholesterol 
(HDL), non-HDL cholesterol (non-HDL), triglycerides (TGC) and TC/HDL levels.  
Postprandial glucose was analyzed two hours after breakfast or lunch using a FreeStyle 
Freedom Lite blood glucose meter (Abbott Diabetes Care Inc, Alameda, CA) according 
to the manufacturer’s instructions. Hemoglobin A1C (HbA1C) was determined in 
duplicate using the Human HbA1C kit (Crystal Chem, Downers Grove, IL) according to 
the manufacturer’s instructions and expressed as percentage of total Hb. 
3.2.6 Blood biomarkers  
Interleukin-6 (IL-6) and tumor necrosis factor-α (TNFα) were determined in 
serum using Human Il-6 ELISA Ready-SET-Go!® (Catalog Number: 88-7066) and 
Human TNF alpha ELISA Ready-SET-Go!® (Catalog Number: 88-7346)  kits 
respectively, according to the manufacturer’s instructions (eBioscience, San Diego, CA). 
Initially, each well of the Corning Costar 9018 ELISA plate was coated with 100µL of 
capture antibody in 1X Coating Buffer, followed by an overnight incubation at 4
o
C. 
Using 250µL/well Wash Buffer and a multichannel pipette, wells were aspirated and 
washed three times following a one-minute soaking to increase washing efficiency. Wells 
were then blocked with 200 µL of 1X ELISA/ELISPOT Diluent and incubated for one 
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hour at room temperature followed by another aspiration and washing. Lyophilized 
standards were reconstituted with deionized water (DI) and allowed to set for 15 minutes 
with gentle agitation. 1X ELISA/ELISPOT Diluent was used to dilute the reconstituted 
standards from 1.5625 to 200pg/mL and 3.90325 to 500pg/mL and IL-6 and TNFα 
respectively; 100µL of this solution was also used to serve as blanks. 100 µL of each 
serum sample and standard was added to its appropriate well in duplicate. The plates 
were then sealed and allowed to incubate at room temperature for two hours. The wells 
were subsequently aspirated and washed five times following the previously mentioned 
protocol. 100µL of detection antibody diluted in 1X ELISA/ELISPOT Diluent was added 
to each well and then incubated for an hour at room temperature. As previously stated 
plates were then aspirated and washed five times. 100µL of Avidin-HRP was added to 
each well and incubated at room temperature for thirty minutes. Aspiration and washing 
of the plate then followed as previously stated five times. 100µL of TMB solution was 
then added to each well and incubated at room temperature for fifteen minutes. Stop 
solution (1M H3PO4) was then added at 50µL to each well and read at 450nm and 570nm 
on the plate reader. 
Plasma adiponectin levels were detected by Human Adiponectin 
radioimmunoassay (RIA) according to the manufacturer’s instructions (Linco Research, 
St. Charles, MO) in the Swine Reproductive Physiology Laboratory at South Dakota 
State University. Dr. Jeffrey Clapper conducted portions of this experiment where 
radioactive materials were used. This protocol was performed twice; first to optimize the 
assay and secondly to run the unknowns. This RIA was performed across two days: day 
one for initial set-up and day two for running the assay.  
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Optimization: Initially tubes were labeled and organized per sample including the serial 
dilutions of the human adiponectin standard (STD). The STD was diluted from 200-0.78 
ng/mL. Next, 300µL of Assay Buffer was added to tubes 3-4 representing the Non-
Specific Binding (NSB) tubes, 200µL was added to tubes 5-6 representing the reference 
tubes or 0ng/mL, 175µL to tubes 25-27, 150µL to tubes 28-30, and 100µL was added to 
the remaining tubes in the assay. Next, 100µL STDs were added in tubes 7-24 from 
lowest to highest, in duplicate. Quality Controls (QCs) were added to tubes 34-39 
representing QC Low 3.125, DC Low 25, and QCLow 200 in duplicate respectively. 
Next, 25 µL of plasma sample “SNA 4-9-13” of test sample was added to tubes 25-27, 
50µL to tubes 28-30, and 100µL to tubes 31-33. Next, 100µL of 125 I-Human Adiponectin 
was added to all tubes followed by the addition of 100µL of Human Adiponectin 
antibody (AB) to all tubes except for tubes 1-4. All tubes were then vortexed, covered, 
and stored overnight at 4
o
C. The next day, 10µL of Rabbit Carrier was added to all tubes 
except tubes 1-2 followed by the addition of 1mL of cold Precipitating reagent (2
nd
 AB). 
All tubes were then vortexed and incubated for 20 minutes at 4
o
C followed by a 20 
minute centrifugation at 2,000 xg also at 4
o
C. Immediately following, the supernate was 
decanted into a waste jug and patted onto absorbent paper. Tubes were then counted on 
the gamma counter, one minute per set of tubes.  
Unknowns: Once optimized, the experiment was then repeated using the same protocol 
as previously stated for the unknown samples with the following modifications. Initially 
tubes were labeled and organized per sample including the serial dilutions of the human 
adiponectin standard (STD). The STD was diluted from 200-0.78 ng/mL. Next, 300µL of 
Assay Buffer was added to tubes 3-4 representing the Non-Specific Binding (NSB) tubes, 
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200µL was added to tubes 5-6 representing the reference tubes or 0ng/mL, and 100µL 
was added to the remaining tubes in the assay. Next, 100µL STDs were added in tubes 7-
24 from lowest to highest, in duplicate. Quality Controls (QCs) were added to tubes 25-
30 representing QC Low 3.125, DC Low 25, and QCLow 200 in duplicate respectively. 
Next, 100µL of each unknown plasma sample was added to their respective tubes in 
duplicate. Then 100µL of 125 I-Human Adiponectin was added to all tubes followed by 
the addition of 100µL of Human Adiponectin antibody (AB) to all tubes except for tubes 
1-4. All tubes were then vortexed, covered, and stored overnight at 4
o
C. The next day, 
10µL of Rabbit Carrier was added to all tubes except tubes 1-2 followed by the addition 
of 1mL of cold Precipitating reagent (2
nd
 AB). All tubes were then vortexed and 
incubated for 20 minutes at 4
o
C followed by a 20 minute centrifugation at 2,000 xg also 
at 4
o
C. Immediately following the supernate was decanted into a waste jug and patted 
onto absorbent paper. Tubes were then counted on the gamma counter, one minute per set 
of tubes. Samples were then rerun if the values obtained for each duplicate didn’t match 
within 10% of each other. RIA sensitivity for this assay was 1085 ng/mL. Inter- and 
Intra-assay coefficients of variance were 5.0% and 11.7% respectively. 
3.2.7 Dietary assessment (Data previously collected and  retrospectively 
analyzed here)  
 A previously validated 3-day food-frequency questionnaire (Appendix 1) based 
on common items in the Hutterite diet was used to assess dietary intake over two 
weekdays and one weekend day for each timepoint. Nutritionist Pro
TM
 (Axxya, 
Woodinville, WA) was used to for diet analysis and nutrient break down of all items 
listed on the food-frequency questionnaires.  
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 3.2.8 Mouse cecum sample SCFA analysis 
Previously collected cecal tissues, from mice fed an RS4 diet, which were snap-frozen in 
liquid nitrogen immediately after sacrifice and stored at -80 
0
C. For each pooled sample, 
three cecal tissues were pooled together (>500mg in total weight) and mixed with 1mL of 
internal standard (2-ethylbutyric acid in 1-butanol, 0.25 mg/ml). Samples were mixed by 
one minute vortexing followed by the addition of 0.5mL of hexane and 2mL of HCl-B. 
Each sample was sonicated for five minutes before purging with an inert helium gas and 
immediately sealed. Each sealed container was incubated in a water bath at 60 
0
C 
overnight in order to catalyze the derivatization of SCFA analytes. Upon returning to 
room temperature, 1.5mL of additional hexane and 15mL of deionized water were added 
to each sample, vortexed for 1 min each and then centrifuged at 3000xg for two minutes. 
The top organic layer (~2mL) was transferred into a 5mL graduated vial before blowing 
down with helium to one-fourth of the volume, increasing the final concentration of 
internal standard from 0.25mg/ml to 1mg/ml. Finally, each sample was transferred into 
150µL insert inside the sampling vial and ~100mg of anhydrous sodium sulfate was 
added prior to being frozen at -20
o
C. GC-MS analysis was carried according to the 
protocol above in section 2.2.3.  
3.2.9 Statistical analysis 
Data was analyzed comparing end-points for outcome variables in CF and RS4 
groups, or pre- and post-intervention measures. For mouse SCFA cecum samples 
intergroup comparisons were performed using Student’s t-test. Linear mixed effects 
models (SAS MIXED procedure) were used to compare the effects of RS4 and CF on 
physiologic parameters. All models included variables for colony and season, where 
38 
 
colony was a surrogate for randomization sequence and season was a surrogate for 
crossover treatment period. General linear mixed models were also used to compare the 
effects of RS4 and CF on microbial abundance using R software package
66
. To correct 
for multiple comparisons, a false discovery rate (FDR or Benjamini Hochberg method) 
correction was used to adjust p values (adjusted p is represented as q). For pre- and post-
intervention comparisons paired t-test (Wilcoxon signed-rank test for non-normal data) 
was used, while student’s t-test (Mann-Whitney signed-rank test for non-normal data) 
was used to compare two different diet groups. Where necessary, data was 
logarithmically transformed to achieve normality. Intra-relationships among parameters 
or bacterial species and inter-relationships between parameters and microbiota were 
carried out using Pearson’s linear correlation coefficient (r). Correlation matrices and 
heat maps were generated using various R-packages. The data were presented as means ± 
S.E.M, unless otherwise noted. A p value of 0.05 or less was considered significant, 
while p value of 0.05 to 0.09 was considered trend or approaching significance. 
3.3  Results 
RS4 was found to improve body composition, dyslipidemia, as well as glucose 
metabolism in this cohort with MetS. Percent body fat, TC, HDL, and nonHDL were 
significant lower after RS4 consumption compared to CF (Table 3-1). A trend towards 
lower waist circumference, fasting glucose, glycated hemoglobin, LDL cholesterol, and 
TNF-α was also observed following RS4 diet compared to CF. Adiponectin was 
significantly followed the same trend as previously mentioned however it was 
significantly increased between baseline and RS4 consumption. Waist circumference, 
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TC, HDL, nonHDL, and IL-6 were significantly reduced from baseline to post RS4, 
while LDL trended towards significance.  
Table 3-1.  Means of biological parameters at baseline and at the end of intervention 
periods
a53
 
 BL Post CF Post RS4 
p: Post 
CF 
vs Post 
RS4 
p: BL 
vs post 
RS4 
Anthropometrics      
Weight (kg) 90.9±3.4 91.0±0.4 91.6±0.4 NS NS 
BMI (kg/m
2
) 32.8±1.1 32.8±0.1 32.7±0.1 NS NS 
Waist (cm) 109.0±2.8 108.8±0.9 106.6±0.9 0.06 0.02 
Systolic BP (mm 
Hg) 
135.0±3.9 134.6±3.5 137.5±3.5 NS NS 
Diastolic BP (mm 
Hg) 
73.7±2.2 68.6±2.0 73.3±2.0 NS NS 
% Body Fat 37.0±1.8 37.7±0.3 37.3±0.3 0.05 NS 
Fat-free mass (kg) 58.8±3.0 58.8±0.3 58.9±0.3 NS NS 
      
Glycemic Variables 
(mg/dL) 
     
Fasting glucose 106.5±4.1 111.5±4.2 101.9±4.3 0.09 NS 
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a
 Data are Least Square Means+SEM adjusting for age, sex, season, colony and baseline 
values.
  
b
 Geometric mean and confidence interval are given for log-transformed triglyceride 
endpoints.   
Postprandial 
glucose 
113.5±11.8 124.3±7.3 114.3±7.5 NS NS 
HbA1C (% of total 
Hb) 
5.89±0.3 5.81±0.1 5.75±0.1 0.08 NS 
      
Lipid Variables 
(mg/dL) 
     
Total cholesterol 196.6±11.6 192.8±4.6 187.8± .9 <0.001 0.01 
HDL cholesterol 43.6±3.3 44.1±1.3 39.8±1.3 <0.01 0.001 
LDL cholesterol 122.7±10.1 117.4±5.6 118.0±6.1 0.06 0.06 
NonHDL cholesterol 153.1±11.8 148.4±4.6 147.5±4.9 <0.01 0.03 
TC/HDL (ratio) 5.0±0.5 4.7±0.2 5.1±0.2 NS NS 
Triglycerides
b
 161.5±19.9 144 (119-
176) 
138 (110-
173) 
NS NS 
      
Blood Biomarkers      
IL6 (pg/mL) 1.3±0.2 1.0±0.2 0.8±0.2 NS 0.04 
TNF-α (pg/mL) 7.9±4.2 9.9±1.2 6.0±1.3 0.08 NS 
Adiponectin 
(g/mL) 
8.3±1.5 10.8±0.4 10.0±0.4 0.02 <0.01 
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p-value ≤0.05 were considered significant, between 0.05 and 0.09 considered as 
approaching significant (trend), when greater than 0.09 is shown as NS (non-significant);   
Linear mixed model analysis was used to determine significance between post-CF and 
post-RS4, paired t-test for baseline vs post-RS4, n=18 to 20 due to missing data points. 
 BL: baseline; CF: control flour; RS4: resistant starch type 4; BMI: body mass index; BP: 
blood pressure; Hb: haemoglobin; HDL: high density lipoprotein; LDL: low density 
lipoprotein; TC: total cholesterol; IL6: interleukin 6; TNF-α: tissue necrotic factor alpha. 
 
Table 3-2.  Estimated nutrients intake at baseline and at the end of intervention 
periods
a53
 
 a
 Data are Least Square Means+SEM adjusting for age, sex, season, colony and baseline 
value analysed by linear mixed model; n=18-20 due to missing data points. 
BL: baseline; CF: control flour; RS4: resistant starch type 4  
 
 16S rRNA sequencing of the gut microbiome resulted in 5,949 OTUs the two 
major phyla present being ~78% Firmicutes and ~9% bacteroidetes. To avoid carry over 
affects between the two week washout period between diets a permutational multivariate 
analysis of variance was performed resulting in no significance which concludes all 
observations observed are directly related to diet.  A principle coordinate analysis (Figure 
3-1) shows 26% and 13% variation between post CF and post RS4 consumption on axes 
Nutrients BL Post CF Post RS4 
p: post CF  
vs post RS4 
Caloric intake (kcal/d) 1774±154 1528±121 1716±128 NS 
Protein (g/d) 76±7 72±5 62±4 NS 
Carbohydrate (g/d) 218±21 220±19 212±18 NS 
Total fat (g/d) 68±7 60±5 53±5 NS 
Cholesterol (mg/d) 415±40 442±38 407±35 NS 
Saturated fat (g/d) 25±3 22±2 21±2 NS 
Monounsaturated fat (g/d) 26±3 22±2 19±2 NS 
Polyunsaturated fat (g/d) 10±1 9±1 7±1 NS 
Total dietary fibre (g/d) 18±2 16±2 27±2 <0.001 
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1 and 2 respectively. RS4 consumption differentially modulated 71 OTUs, 65 Firmicutes, 
3 Bacteroidetes, 1 Actinobacteria, 1 Tenericutes, and 1 Proteobacteria. Interestingly, all 3 
Bacteroidetes were increased by RS4 consumption whereas the Firmicutes had a mixed 
response.  
 
Figure 3-1: Separation of the microbiome post intervention in RS4 and CF groups. 
Two-dimensional principal coordinate analyses (PCoA) based on the weighted 
UniFrac distance between samples, given the abundance pf 5,831 taxa present in at 
least one sample (n=19). Axes 1 and 2 explain 26% and 13% of the variation, 
respectively (p=0.01)
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Firmicutes and Bacteroidetes are commonly studied in relationship to the obese 
microbiome. Both phyla contain both beneficial and less desired microbes. Figure 3-2 
shows that overall the RS4 intervention reduced the Firmicutes:Bacteroidetes ratio, a 
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desired attribute of prebiotic fibers, whereas CF increased this ration. Of important note 
alterations of this ration are highly individual specific, grouped together these trends were 
observed. Variation of the gut microbiome is dependent on substrate availability for 
microbial fermentation as well as total caloric intake
36
. Seasonal variations of the 
microbiome have been reported in previously, attributed to fresh fruit and vegetable 
availability in the Hutterite diet
35
; this was ruled out in this case as the study period did 
not overlap with winter months. Table 3-2 indicates macronutrient intake did not vary 
across study periods based on the self-reported 3-day diet questionnaire. Total dietary 
fiber was however significantly greater after RS4, however caloric intake was not 
significant.   
 
Figure 3-2: The Firmicutes/Bacteroidetes ratio after intervention (n = 14). The 
dotted line represents this ratio at baseline.
53
 
 
 A Pearson correlation analysis showed a potential link between significant 
changes in the gut microbiota composition induced by RS4 and altered SCFA levels 
shown in Figure 3-3. Acetate and butyrate levels were correlated (p < 0.05) with 
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Ruminococcus lactaris (r = 0.54) and Oscillospira spp. (r = 0.41). Total SCFAs were 
correlated with the abundance of two species: Methanobrevibacter spp. (r = 0.43) and 
Ruminococcus lactaris (r = 0.52). Propionate and isobutyrate levels were linked to 
Methanobrevibacter spp. (r = 0.65 and r = 0.79, respectively), Eubacterium dolichum (r = 
0.42 and r = 0.43, respectively), Christensenella minuta (r = 0.39 and r = 0.59, 
respectively), and Ruminococcus lactaris (r = 0.59 and r = 0.40, respectively), of which 
the latter two were increased by RS4. These associations with specific microbes and fiber 
were not found in the CF group.  
 
Figure 3-3: Positive correlation of six bacterial species with increased SCFA levels in an RS4-specific 
manner (all, p <0.05). Pearson coefficients are shown on heat map. #, the closest hit from the NCBI 
16S rRNA database cross referenced with the OTU from the Greengenes database. †, species either 
significantly enriched or approached significance in the RS4 group.
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 In the KK.Cg-A
y
/a mouse model, cecal butyrate was found to be significantly 
enriched via RS4 consumption compared to control diet as shown in Figure 3-4. SCFAs 
acetate and propionate were virtually undetected in these cecum tissues. Neither RS4 nor 
45 
 
the control diet significantly enriched isobutyrate, valerate, isovalerate, and heaxanoate 
concentrations.  
 
Figure 3-4: Cecal butyrate concentration in KK.Cg-Ay/a mice fed with RS4 and 
control diets. Data points represent the mean ± SEM (n = 3). *p<0.05, **p<0.01, 
***p<0.001 compared with control diet group.
65
  
3.4  Discussion 
The results of this chapter further support the use of RS4 as a dietary supplement 
relative to MetS symptoms. Waist circumference and % body fat were significantly 
reduced by RS4 compared to CF, both of these variables may contribute to reduced 
central obesity, the number one diagnostic criteria of MetS. Adiponectin was 
significantly lower after RS4 compared to CF, however it was higher after RS4 compared 
to baseline. The plasma reduction in TC, HDL, and nonHDL cholesterol was also 
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observed in the parent cohort of this study
2
 This is undesirable adiponectin is inversely 
related with MetS. 
It has been well established that type and quantity of fiber in the diet differentially 
modify the gut microbiome
36
. Here we found that 71 OTUs were differentially affected 
by the supplementation of RS4, this finding was highly variable by each individual. The 
Firmicutes:Bacteroidetes ration has been well established as a predictor of the obese 
microbiome
29,30
. 
The ability to correlate the outcome of the method optimized in chapter two with 
results in this chapter was a significant outcome of this overall research study.  
The mouse model studied in this chapter support the increased butyrate production in 
this human population as found in chapter 2. Applying the SCFA extraction method to 
intestinal tissue proved to be a challenge at first. The study protocol was initially 
attempted following the same guidelines as described in section 2.2 using one cecum 
sample; however, GC-MS resulted in undetectable concentrations of SCFA. In an effort 
to save the remainder of these delicate samples, pools of three samples were established 
to increase SCFA concentrations as well as using HCl-B overnight as a derivatization 
reagent instead of BF3-B for 20 minutes. Of note, after the overnight incubation with 
derivatization reagent, the sample completely dissolved into solution whereas before it 
appeared to be washed clean. This resulted in detectable and quantifiable SCFA 
concentrations.  
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CHAPTER 4 . SUMMARY 
 The goal of this research was to optimize a matabolomic assay to quantify fecal 
short chain fatty acids (SCFAs), a byproduct of microbial fermentation in the gut, and to 
apply this assay to assess associations of various phenotypic outcomes of RS4 
intervention in an adult population with MetS as well as in genetically induced obese 
mice. This protocol was created for scientists at SDSU to extract, derivativatize, and 
quantify short chain fatty acids from stool samples and may in future be extended to 
quantify medium  chain fatty acids from stool samples. Overall, metabolite profiles 
related to the gut microbiota can offer deep insights on the impact of lifestyle and dietary 
factors on chronic diseases, which is why metabolomics studies in gut microbiota related 
research have increased in last few years. The protocol may be utilized for other complex 
matrices such as intestinal samples, as described in Chapter 3. The resulting method 
contains a one-step derivatization followed by a simple extraction. BF3-B and HCl-B 
were chosen as derivatization reagents because the combination of these powerful acids 
with methanol and/or butanol are efficient catalysts for the esterification of fatty acids
67
. 
Naturally fatty acids are difficult to analyze due to their high polarity and volatility which 
causes sample loss either in the air or by surface absorption. The addition of a 
derivatization step causes esterification which attaches a functional group to the fatty acid 
structure creating a larger more stable molecule which are easier to detect. The final 
working protocol is as follows: 
Chemicals: 
 Boron trifluoride-1-butanol (BF3-B) 
 Hexane (>97.0%) 
 1-butanol 
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 Sodium sulfate (granular, anhydrous, >99.0%) 
 Internal standard (2-Ethylbutyric acid 99%) 
 Helium (gas) 
 Deionized water 
Instruments: 
 Vortex  
 Centrifuge 
 Pipettes  
 Balance 
 Water bath 
 30mL tube with Teflon cap 
 GC sampling vial 
 50mL centrifuge tube 
 Sonicator 
IS prep: 
(Prepare IS in butanol if no exact balance available and proceed with sample prep by 
adding exactly 1mL of IS solution to the sample) 
1. Prepare a 1.5mg/mL IS in 1-butanol (record the exact weight of 2-ethylbutyric 
acid) 
2. Pipette 1mL into 30mL tube 
3. Record weight of 30mL tube + IS 
Sample Prep: 
1. Weigh at room temperature 800-1000mg (±0.1mg) in the tube with the IS 
2. Add 500 µL hexane 
3. Vortex for 1 min. 
4. Add 2 mL HCl-B reagent 
5. Vortex for 1 min. 
6. Sonicate for five minutes 
7. Purge the container with an inert gas (Helium)  
8. Close and seal the container 
9. The reaction is conducted at 100 ͦ C for 20 minutes 
10. Cool it down to room temperature 
11. Add 1.5 mL hexane 
12. Vortex for 1min.  
13. Add 15 mL H2O and vortex for 1 min. 
14. Transfer to 50mL centrifuge tube 
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15. Centrifuge for 2 min at 3,000g*min-1. 
16. Transfer the upper organic layer into a 2 mL GC vial with or without 150µL insert 
17. Add ~100mg sodium sulfate 
18. Seal the vial and keep it at -20C 
  Stepping through this protocol one should note the importance of using a glass 
vial to prevent any surface absorption of the volatile fatty acids. Teflon caps are used to 
ensure an adequate and material/solvent compatible seal. Initially the IS was prepared at 
2mg/ml in acetone, the solution was evaporated off via purging with in inert gas (either 
nitrogen or helium pending availability) and the exact weight of the IS was obtained. This 
method was found to be too variable due to solvent splashing and spilling pending air 
flow rate. The concentration of IS was then reduced to 1.5mg/ml and directly prepared in 
1-butanol. Upon the addition of hexane and the derivatization reagent, adequate mixing 
must be performed as the sample tends to stick to the glass and/or lid. Proper mixing was 
achieved via sample vortexing both upright and upside down for complete wash of the 
sample tube. Also important to note is that the derivatization reagent must be closed 
immediately after use as it reacts with water in the air. Sonicating the sample produces a 
significant amount of heat, caution should be taken as to how the tubes are handled. Once 
samples are purged with helium, the tube should be capped immediately. Heat is applied 
in the water bath to help drive the derivatization reaction forward. After the water bath, 
samples must be returned to room temperature before opening to prevent any loss of the 
volatile acids. 
The results of this research also support supplementation of RS4 into the diet of 
individuals with MetS; however, a significant amount of research is still needed to 
establish dietary reference intake values. We found that RS4 supplementation 
significantly increased fecal SCFA (butyrate, propionate, hexanoate, valerate, and 
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isovalerate) which directly correlated with beneficial gut microbiota. We also found that 
RS4 supplementation significantly reduced waist circumference, TC, HDL, nonHDL, and 
IL-6 which may provide alleviation of MetS and its comorbid diagnoses. Compared with 
the CF, RS4 significantly decreased % body fat, TC, HDL, nonHDL cholesterol, as well 
as adiponectin. RS4 supplementation in this cohort also reduced the 
Firmicutes:Bacteroidetes ratio as well as promoted growth of several beneficial microbial 
species.  Taken together we found that RS4 in association with the gut microbiome elicits 
beneficial immunometabolic health outcomes on adults with metabolic syndrome.   
The results of this study lead to many future implications and study ideas such as 
confirming the results by humanized gnotobiotic mouse model such as that described in 
the drafted protocol in Appendix 2. This gnotobiotic mouse model would be used to 
confirm that the results of the findings above were directly associated with gut microbial 
change. In brief, stool from human RS4 responder would be orally gavaged into 
gnotobiotic mice that would then be placed on RS4 or CF diet. The same parameters as 
above would be studied on these mice. This mouse model was originally the plan of this 
graduate study however due to university restrictions and lack of collaboration with 
outside facilities in the local area; we were unable to conduct the experiment and the 
protocol was left in draft form.  
In conclusion, with the national trend of obesity and chronic diseases associated 
with obesity continue to rise at an alarming rate; it is evident that research needs to be 
completed to assist in reversing this epidemic trend.  Overall, the research presented 
within this paper were beneficial in understanding the effect of an ad libitum RS4 dietary 
intervention on various health parameters in humans and mice.  Even though some data is 
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inconclusive within this experiment, a solid foundation has been established for future 
research studies.  The tools have been created and are ready for use to continue on with 
this intriguing research on dietary interventions and their influence on microbial-derived 
SCFA production.Implementing prebiotic and higher amounts of dietary fiber within the 
diet suggest improved health outcomes. The outcomes of this research may contribute in 
the development of future dietary guidelines of RS in the diet. With further research and 
testing, I am hopeful for breaking evidence suggestive of creating a healthier nation.    
This research should also help future clinical and mechanistic research.  
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Appendix 1. Gnotobiotic IACUC Protocol  
 
 
 SOUTH DAKOTA STATE UNIVERSITY 
 ANIMAL USAGE FORM  
 EXPLANATIONS AND INSTRUCTIONS 
 
     Individuals from academic institutions that receive funding from federal granting agencies such as NIH, 
NSF and USDA are required, by federal regulations, to follow specific guidelines concerning the care and use 
of vertebrate animals (mostly mammals) used in their research.  Part of these requirements include the 
completion of an animal usage form which must be reviewed and approved by the university animal care 
committee before grants utilizing vertebrate animals can be submitted, and before experiments utilizing 
vertebrate animals can be initiated.  Therefore, complete the form as completely and as clearly as possible and 
send to University Veterinarian, Department of Veterinary Science, SAR 106, Box 2175, SDSU.  If you have 
any questions, call the University Veterinarian at 688-6528 or 688-6649. 
  SOUTH DAKOTA STATE UNIVERSITY 
 ANIMAL USAGE INFORMATION FORM 
Instructions: Complete all items.  If items do not apply, write "N/A" on the appropriate line.  Send 
form to Veterinarian, Animal Care and Use Committee, SAR 106, Box 2175, South Dakota State 
Univ. (688-6649).  
1.  Principal Investigator/Instructor:  Moul Dey    Date:   
11/15/2013       
2. Department:      Health and Nutritional Sciences  
 Campus Address:  Bldg/Room    Wagner Hall/ 449    Box  2203     
 E-mail:   Moul.Dey@sdstate.edu      
3. Phones: Office   605 688 4050  , Laboratory 605 688 6169    , Emergency                 
 For IACUC Committee Use Only 
Proposal Number  
 
This form will be updated yearly and expires December 31, 2013. 
Please destroy all old forms. 
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4. Funding Agency or Department:     AES  
5. a) Proposal Submission Deadline:     11/15/2013   
 b) IACUC Approval Period (not to exceed 3 years):    11/26/2013-11/25/2016   
6. Project Title:     Study of metabolic status and gut microbial profiles associated with human 
fecal transplantation in a mouse model  
7. Animals to be used in the project: 
A.  Species B.  Number of 
animals to be 
acquired from 
outside SDSU 
C.  Number of 
animals to be 
utilized 
involving no 
pain* or distress  
D.  Number of 
animals subjected to 
pain or distress for 
which appropriate 
drugs will be used.† 
E.  Number of animals 
subjected to pain or 
distress for which 
appropriate drugs will 
adversely affect the 
results**† 
F.  Total number 
of animals (Cols. 
C + D + E) 
Mouse 48  48  48 
      
*  Pain = pain induced for reasons other than normal animal husbandry practices (other than single or routine venipuncture 
& non-irritating injections) 
** An explanation of the procedures producing pain or distress in these animals and the reasons such drugs were not used 
must be included in this submission  
†  Must complete question 14 
Source of Animals      Taconic Inc., Rensselaer, NY   
Housing location:   Building     ARW   Room    TBD     
If the animals will be housed & cared for in ARW, you must contact the ARW facility 
manager (diane.baker@sdstate.edu, phone 605-688-6028) two weeks before the 
anticipated arrival date. 
  Other          
8. For agricultural animals, will accepted management procedures and routine practices such 
as castration and dehorning as described in the GUIDE FOR THE CARE AND USE OF 
AGRICULTURAL ANIMALS IN RESEARCH AND TEACHING (Third Ed., 2010) be 
used in the care of these animals?   
 (Available from http://www.fass.org/docs/agguide3rd/Ag_Guide_3rd_ed.pdf) 
           Yes                  No.  If NO, then describe exceptions. 
9. Provide a complete description of the proposed use of animals.  You must refer to the 
specific  sections and page numbers in your proposal or include on an attachment with a full 
description. 
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The principal objective of the proposed use of animals is to validate and extend our previous 
findings in humans that showed resistant starch-type 4 (RS4), a chemically modified resistant 
starch present in the wheat flour, promotes the metabolic health (Nichenametla et al., 2014). 
Using human stool samples from this study; we would like to investigate the direct interaction of 
RS4 with gut microbiota in a pre-clinical mouse model where we can customize the gut 
microbiota profile unlike in humans. Hence, gnotobiotic mice model with a defined gut 
microflora is the optimum model for human-to-mouse fecal-transplantation because these mice 
associated with Altered Schaedler Flora (Table 1) show the potential to mimic human gut 
microbial profile in mice . We are also able to directly reference a large database of prior work 
using such humanized mice, especially for gut-microbiota associated obesity and metabolic 
syndrome supporting the use of gnotobiotic mice. 
Table 5: Altered Schaedler Flora [commensal, non-pathogenic?] also need original 
reference 
Taxon Oxygen sensitivity Identity 
Fusiform EOS bacteria Yes Clostridium sp ASF356 
Fusiform EOS bacteria Yes E. plexicaudatum ASF492 
Fusiform EOS bacteria Yes Clostridium sp. ASF502 
Fusiform EOS bacteria Yes Clostridium sp. ASF500 
Lactobacillus acidophilus  No Lactobacillus sp. ASF360 
Lactobacillus salivarius No L. animalis & L. murinus ASF361 
Bacteroides distasonis No Bacteroides sp. ASF519 
Spiral shaped organism No Flexistipes phylum ASF457 
 
Dietary interventions with RS-2 and RS-4 have been shown to attenuate various risk factors for 
metabolic syndrome (MetS) characterized by several conditions such as insulin-resistance, 
dyslipidemia, abdominal obesity and hypertension that ultimately lead to atherosclerosis and 
cardiovascular disease (CVD) (Martinez et al., 2010; Brunner et al, 2002). As RS4 is chemically 
modified and therefore can evade chemical digestion, it is however susceptible to microbial 
fermentation in the colon, hence we are interested in showing how the interaction between RS4 
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and gut microbiota renders a healthy outcome. Accumulating evidence suggests that gut 
microflora play a central role in maintaining a balance between health and disease, including 
MetS 
29
. Moreover, it has been postulated that there are different sets of gut microbiota based on 
abundance in healthy individuals versus patients with MetS 
68
. Hence, we hypothesized that 
dietary RS4 would prevent MetS by shifting the blood, lipid and gut microbial profiles towards a 
favorable health-outcome after transplanting human fecal samples from MetS patients to 
gnotobiotic mice.  This gnotobiotic mouse model, once optimized, can be utilized for future 
research concerning the microbiome which is the field of growing interest.  
Prior to animal experiment, we will obtain the formulated control and RS4 feeds (Test Diet, 
Richmond, IN) (Table 2). These isocaloric control and RS4 diets will eliminate the possible 
effects of energy restriction in metabolic health of mice. 
Table 2: Composition of experimental diets 
Ingredients Control Diet (%) RS4 Diet (%) 
Wheat starch
1
 31.77 27.07 
Resistant wheat starch type-4
2
 0.00 23.5 
Powdered cellulose 18.80 0.00 
Casein – vitamin free 14.00 14.00 
Dextrin 13.67 13.67 
Sucrose 8.82 8.82 
Soybean oil 8.00 8.00 
AIN 93M mineral mix 3.50 3.50 
AIN 93M vitamin mix 1.00 1.00 
Choline Bitartrate 0.25 0.25 
L-Cystine 0.18 0.18 
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t-Butylhyrdoquinone 0.0008 0.0008 
Energy content (Kcal/g) 3.3 3.3 
1
 Wheat starch is Midsol TM 50 with energy content of 359.5 Kcal/100 g. 
2
 Resistant starch is Fibersym RW with energy content 56.5 Kcal/100g. 
 
Overall mice experiment will be carried out in two phases: 
Phase I: Microbial effects of animal health status 
To know how the microbiome of mice transplanted with human feces responds to RS4 dietary 
intervention, we will use a gnotobiotic mouse model consisting 5-8 week old female 
heterozygous Swiss nude mice randomly divided into four groups (12 mice per group, two 
sacrificed for baseline values, and five mice per final two cages) for human fecal transplantation 
(Table 3). We chose this strain because of its availability with a defined gut-microbiota. All mice 
will be kept in more stringent specific pathogenic free housing to prevent contamination with any 
unknown bacteria 
Table 3: Mouse groups and treatments 
Group Diet No. of animals Dose/treatment 
A (A1+A2), 2 
donors 
Control 12 (-2 sacrifice, 5+5: final) 200µL preRS4 
B (B1+B2) Control 12 (-2 sacrifice, 5+5: final) 200µL post-RS4 
C (C1+C2) RS4 12 (-2 sacrifice, 5+5: final) 200µL preRS4 
D (D1+D2) RS4 12 (-2 sacrifice, 5+5: final) 200µL post-RS4 
 
After one week of acclimatization, mice will undergo a fecal microbial transfer (FMT) from an 
individual whose response to RS4 was greatest compared to other participants. Response to RS4 
was analyzed on several parameters including change in body fat, weight, total cholesterol, 
fasting blood glucose, metabolic status, and specific bacterial abundance. One pre-RS4 and one 
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post-RS4 fecal sample will be homogenized and added to 5mL of PBS to create the solution for 
subsequent gavage. 200µL of prepared fecal solution will be gavaged into the stomach of the 
recipient mice through plastic oral tubing. After fecal transplantation four groups each with 11 
mice (Table 3) will be housed separately to avoid possible cross-contamination.  One mouse 
from each of the four groups as indicated in Table 3 will be sacrificed prior to FMT to obtain 
cecal short chain fatty acids analysis. After three weeks, the blood samples will be collected from 
saphenous vein to take the basal readings of blood glucose and lipid profiles before dietary 
intervention. This method of blood collection does not involve anesthesia and is less stressful to 
mice. Collection of fecal pellets followed by fecal culture will be performed every week for 
analysis of gnotobiotic status throughout the entire experiment. At this point one additional 
mouse will be sacrificed from each group for basal body composition prior to dietary 
intervention, leaving the final total of ten mice per group.  
Phase II: Impact of dietary intervention with RS4 on animal health status 
Phase II of this experiment includes the addition of RS4 chow to animal groups C and D as 
indicated in Table 3. Mice will be observed daily and monitored for any abnormal signs of pain 
and distress, appearance, appetence and behavior. All mice will be weighed weekly to monitor 
the feed intake and growth curve. We will consult to attending veterinarian for appropriate care, 
treatment or euthanasia, if and when any mouse develops visible signs of distress. All mice will 
be euthanatized with CO2 asphyxiation 21 days post-dietary intervention (week 7), and blood will 
be collected through cardiac punctuation immediately after the sacrifice. Body composition 
analysis will be performed at the Materials Evaluation and Testing Laboratory (METLAB) in the 
College of Engineering at SDSU. Biological specimens including the entire gut, mesenteric 
lymph node, mesenteric fat, spleen, and liver will be collected, and aliquots of tissue samples will 
be snap-frozen in liquid nitrogen or kept in 10% formalin for subsequent gene expression 
experiments  or histopathological examinations, respectively. The remainder of the mouse will be 
disposed and incinerated later.  The summarized timeline of the proposed experiment is shown in 
Table 4. 
Table 4: Schedule of the proposed experiment 
Week Treatment Comments 
0 Acclimatization Daily observation; regular chow diet 
1 Fecal Microbial Transplant  Phase I: Blood collection through 
saphenous vein, 200µL oral gavage of either 
preRS4 or post-RS4 human stool samples. 
One animal from each of the four groups 
will be sacrificed for baseline values 
4 Introduction of control or RS4 chow to Phase II: Blood collection through 
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designated groups saphenous vein, one animal from each of the 
four groups will be sacrificed for analysis of 
microbial effects pre-diet intervention 
 
7 Mice sacrifice and tissues collection CO2 euthanasia  
Body composition; cardiac puncture; snap-
frozen tissues in liquid N2; fixed-tissues in 
10% formalin 
Routine monitoring of animal health includes daily observation of any signs of pain and distress, weekly 
measurement of body weight, and weekly microbial culture of stool samples. 
10. Provide specific design information that supports your rationale for involving animals and 
appropriateness of species and numbers to be used.  (Note:  This proposal may be referred 
to a statistician to verify appropriateness of animal numbers.) 
The Swiss nude mice model has been well established for human fecal transplantation. The 
design of this project is based on previous literature reports on human-to-mouse fecal 
transplant models. As similar kind of fecal transplantation studies are not feasible in 
humans, appropriate mouse model is.  The numbers of animals in this study are consistent 
with literature reports using mouse model for human fecal transplantation. The study 
reporting human-to-mouse fecal transplant model is given below: 
We are also able to directly reference a large database of prior work using such humanized 
mice, especially for gut-microbiota associated obesity and metabolic syndrome supporting 
the use of gnotobiotic mice. 
Ridaura, V. K., Faith, J. J., Rey, F. E., Cheng, J., Duncan, A. E., Kau, A. L., . . . Gordon, J. 
I. (2013). Gut microbiota from twins discordant for obesity modulate metabolism in mice. 
Science, 341(6150), 1241214. doi: 10.1126/science.1241214 
11. Alternatives to Painful Procedures: 
 If painful or slightly painful procedures are to be used, provide a written narrative 
description of the specific electronic database/information search (in addition to reading 
journals/periodicals) which was performed (for example, the Animal Welfare Information 
Center) along with the specific key words to help determine that alternatives are not 
available.  
 
Date search was conducted:    11/04/2013    
 
Key words used:       Gnotobiotic, Gut microbiota, Metabolic syndrome, Resistant Starch, 
Mouse model  
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Databases searched:      Pubmed  
 
Period of time covered by search:      All years  
 
Narrative description describing the results of the alternatives search and the impact on 
the use of animals in this project: 
 
Oral gavage is the straight-forward and less painful than other techniques for the fecal 
transplantation. Blood collection through saphenous vein is less painful because it is less 
invasive than retro-orbital sinus, which may have more complication.  
12. Check if proposal involves (refer to IACUC page on InsideState for more information) 
       Invasive Procedures (e.g. multiple injections, multiple blood sampling, surgery, 
catheterization) 
      X  Pain or other Stress (e.g. injections, disease, surgery, Freund's adj., ascites fluid 
production) 
        Deprivation (e.g. limiting food, water, light) 
        Other (e.g. fright, noise, physiological stresses, etc.) 
 Briefly describe any items checked above and explain the need for these in the project. 
Only one-time oral gavage will be used  during the entire study. We will also collect 
the blood form saphenous vein twice three weeks apart.   
13. A. For any of the procedures described above in question #13, identify the 
pharmaceuticals used to minimize discomfort to the animals: 
                Route of 
  Type  Dosage Administration 
 Anesthesia              
 Analgesia              
 Tranquilizer              
 Euthanasia    CO2    To affect    Inhalation  
 B. If no pain relieving measures are used, please justify: 
C. If controlled substances will be used in the protocol, whose DEA and State of South 
Dakota controlled substances registration will the agents be purchased and used under?   
NA 
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14. Describe any additional approaches taken to minimize pain or discomfort, to control 
infections, or otherwise insure the humane treatment of animals in this project.  Also 
describe how the animal care personnel will be trained. 
Any animal suffering undue pain or distress will be humanely euthanized during the study 
period.  Animals will be maintained at the SPF level (autoclaved food and bedding, 
acidified water). If signs of discomfort, injury or infections are observed, the veterinarian 
will be consulted, and appropriate care will be provided and recorded. If the animals 
develop untreatable diseases, the veterinarian will determine if euthanasia should be applied 
before the ending of the study. All personnel are trained in how to handle mice in a way 
that minimizes stress to the animals. 
15. If animals will be euthanized, describe the procedures to be used and method and site of 
disposal.   Unless a deviation is justified for scientific or medical reasons, methods should 
be consistent with the most current version of the AMVA Guidelines on Euthanasia 
(http://www.avma.org/issues/animal_welfare/euthanasia.pdf).  If animals will not be 
euthanized as part of the research project, describe their further use or plans for their 
disposition; include euthanasia method for emergency situations.  
All animals will be euthanized using CO2 at the ending of study or whenever required. 
Blood of euthanized animals will be drawn via cardiac puncture. Biological specimens of 
euthanized animals that die or euthanized will be harvested, snap-frozen in liquid nitrogen 
and stored in a -80ºC freezer, and used for this study. The rest of the carcasses will be 
incinerated. 
NOTE:  Animals are subject to post-mortem examination if unexplained death occurs 
which is not a part of research protocol.  Necropsy will be performed under the direction of 
the attending veterinarian and/or the ADRDL.  Laboratory confirmation will be provided 
by the ADRDL.  Researchers will be charged the standard fee for these services. 
16. Evaluate the effect on this project of using alternative procedures not including animals. 
In vitro cell-culture models are not adequate to represent the entire process of gut microbial 
interaction and ecology in health and diseased status. We cannot use conventional mice 
model because they contain a vast variety of gut microbiota, which may potentially conflict 
the outcomes.  Hence, mice model with defined flora is the optimum model for our intent, 
where we can control the confounding variables unlike in humans. 
17. Human health risks  (Note:  If this project is deemed to have significant human health risk, 
it may be referred to the Institutional Biosafety Committee.) 
A. What are the human health risks to which investigators and other contact personnel will 
be subjected in working with animals in this project?  Include physical, zoonotic, and 
allergic risks. 
Bites, scratches and allergies are potential human health risks for the personnel. 
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B. What approach will be taken to minimize those risks, and how will laboratory and 
animal care personnel be trained with regard to the risks? 
The personnel on this project are trained in handling laboratory mice and in the procedures 
taken in the protocol. The training and previous experience will minimize the above risks. 
The mice will arrive here as SPF with defined flora and will be kept in strict SPF 
environment. Personnel will wear gloves and lab coats while handling mice. These will 
effectively prevent the potential human health risks.  
18. Personnel 
 A. Appropriate medical care for all animals will be available and provided as necessary by 
a licensed and accredited veterinarian.  Standard husbandry practices as defined in the 
Guide for the Care and Use of Agricultural Animals in Research and Teaching Chapter 
3 may be carried out by other trained individuals, as appropriate.  Specify whether 
veterinary care will be provided by the SDSU veterinarian or a consulting veterinarian 
(provide the name of the individual involved with the project):  
     Dr. Michele Mucciante  (name of SDSU veterinarian or 
consulting veterinarian) will provide the veterinary care and has been notified by me. 
 B. Education and Training Programs.  Public Laws 99-158 and 99-198 require the 
University to establish education and training programs to scientists and animal 
technicians who handle and care for laboratory animals.  Personnel must complete 
training from the Collaborative Institutional Training Initiative (www.citiprogram.org) 
read the appropriate SDSU training materials and/or view the appropriate tapes/CDs 
and then sign a certification statement.  Animal Usage Forms cannot be processed until 
all persons handling and caring for the animals have signed certification statement on 
file.  Contact Janice Kampmann, ADR 106, phone 688-6649. 
      C. Additional training in specific techniques (restraint, anesthesia, euthanasia, injections, 
etc.) are available through the University Veterinarian.  The principal investigator's 
signature on the bottom of this form is taken to indicate that training and education 
requirements have been fulfilled. 
D. List RESEARCH PERSONNEL who will have direct animal contact.  Include their 
position (principal investigator, graduate student, etc), their specific role in the project, 
years of experience working with the species proposed to be used in the project, and 
years of experience conducting the procedures they will be doing in the project. 
Name Position Role in Project Experience 
(years) working 
with the 
proposed 
species 
Experience 
(years) 
with 
procedures 
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Moul Dey   Principal Investigator Oversight of the entire project 9 9 
Robert Juenemann Graduate Student Preparation of the reagents for 
fecal transplantation, Animal 
care 
Collection of biological 
specimens 
CO2 euthanasia 
1 1 
Bijaya Upadhyaya Graduate Student Animal care, Blood collection 
through saphenous vein, 
Cardiac puncture, Collection of 
biological specimens,  
3 3 
David Knudsen  Professor Oversight of animal housing 
and health, histopathology 
>20 years >20 years 
TBD Undergraduate Student Animal care and management Will be 
trained 
 
 
E. For research personnel that have not worked with animals before and/or have not 
previously conducted the procedures described in this protocol, describe how training 
for these individuals will be conducted.        
 19. ASSURANCE BY INVESTIGATOR: 
 I assure that these activities do not unnecessarily duplicate previous experiments conducted 
here or elsewhere.  I agree to conduct this project in accordance with applicable provisions 
of the Animal Welfare Act, the Public Health Service (PHS) Policy on Humane Care and 
Use of Laboratory Animals, the Guide for the Care and Use of Laboratory Animals, other 
applicable federal laws, the laws of the State of South Dakota, and the policies of South 
Dakota State University.  All necessary State and Federal permits have been obtained, as 
appropriate.  I agree to conduct this project in accordance with the protocol submitted to the 
Animal Care and Use Committee, to ensure that all research personnel are aware of and 
follow the approved protocol, and to obtain prior approval from the committee before 
modifying the protocol. 
 Signature of the Investigator     Date      
 
* * * * * * * * * * * * * * * * * * * * * * * * * * * * *  
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 For Committee Use Only:  
 Date received                               ; Date Routed                     ; Deadline for Review        
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Appendix 2: 3-Day Food Checklist 
3-Day Food Checklist 
 
Name:____________________________________ ID:______________
 Date:_________________ 
 
Instructions 
 Fill out one Food Checklist throughout the day on the three days marked below: 
 Sunday    Monday    Tuesday    Wednesday    Thursday    Friday    Saturday 
 Complete each Food Checklist by marking an ‘x’ in the box each time you ate a food on that day 
(not what was available. 
 For example, if you drank a cup of milk at breakfast and one at lunch, you would mark 2 boxes.  If 
you had 2 slices of bread at breakfast and 2 at dinner you would mark 4 boxes. 
 If you had soup, be sure to mark it under the type of broth and also mark the vegetables or meat 
that was in the soup. 
 
Day 1 
Mark how many servings of each of the following you ate. 
 
Dairy – include flavored milks  (serving = 1 
liquid cup or 1 slice or oz for cheeses) 
Milk – whole         
Milk – 2%         
Milk – 1% or skim        
Margarine or butter (pat)        
Yogurt, all kinds        
Cheese, all kinds         
Ice Cream or sherbert (1/2 c)        
 
Beverages (serving = 1 cup) 
Fruit juice (orange, grape, etc.)         
Vegetable juice (tomato, etc.)         
Wine or beer         
Coffee         
Tea         
Pop, kool-aid, or punch         
Pop, kool-aid, etc. DIET         
Water         
How many tsp of sugar do you put in your coffee  
and/or tea? _____ teaspoons 
Breads, Cereals & Grains 
Bread, wheat (1 slice)        
Bread, white (also biscuits, buns)        
Noodles, dumplings (also 
knödel, spätzel) (1/2 c) 
       
Maultauschen, cottage 
cheese pockets, etc. (1 item) 
       
Oatmeal or oat cereal (1 c)        
Rice or rice cereal (1 c)        
Other grains (1 c)        
 
Eggs, Fish, Poultry & Meat   
(1 serving = 3 oz = 1 deck of cards) 
Eggs (1)        
Turkey or chicken         
Sausage (include Thanksgiving sausage)        
Pork        
Beef        
Lunch meat (also chopped ham)        
Did you eat the skin on your turkey or 
chicken? 
 No       Yes      Sometimes, not 
always 
Fruits (serving=1 item or 1 cup) 
Apples        
Oranges        
Banana        
Melons        
Other fruit        
 
Vegetables (serving=1 item or 1/2 c) 
Potatoes – fried (1 med)        
Potatoes – baked (1 med)        
Potatoes – boiled (1 med)        
Lettuce        
Tomatoes (1)        
Beans, green (1/2 c)        
Carrots, peas, corn        
Beets        
Squash        
Cauliflower & broccoli        
Cabbage (not sauerkraut)        
Other vegetables        
 
Sweets, Crackers, Pickles & Soups 
Cake or cookies (2)        
Pie (slice) (also kuchen&strudel)        
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Candy (also chocolates, bars, 
hard candy, etc.) 
       
Crackers (2) (include saltines)        
Pickled foods (1 Tblsp) (ex. 
pickles, watermelon, tomatoes, 
corn relish) 
       
Sauerkraut        
Soup – milk- based broth        
Soup – clear broth        
 
Thinking about the meat you had today. 
About how many of these servings were 
fried? 
 All    Most    Some    None    Did not 
have any 
 
Did you eat anywhere not on the colony 
today?  
 Yes    No    If yes, 
describe__________________ 
 
Any other foods? 
____________________________
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Day 2 
Mark how many servings of each of the following you ate. 
 
Dairy – include flavored milks  (serving = 1 
liquid cup or 1 slice or oz for cheeses) 
Milk – whole         
Milk – 2%         
Milk – 1% or skim        
Margarine or butter (pat)        
Yogurt, all kinds        
Cheese, all kinds         
Ice Cream or sherbert (1/2 c)        
 
Beverages (serving = 1 cup) 
Fruit juice (orange, grape, etc.)         
Vegetable juice (tomato, etc.)         
Wine or beer         
Coffee         
Tea         
Pop, kool-aid, or punch         
Pop, kool-aid, etc. DIET         
Water         
How many tsp of sugar do you put in your coffee  
and/or tea? _____ teaspoons 
 
 
Breads, Cereals & Grains 
Bread, wheat (1 slice)        
Bread, white (also biscuits, buns)        
Noodles, dumplings (also 
knödel, spätzel) (1/2 c) 
       
Maultauschen, cottage 
cheese pockets, etc. (1 item) 
       
Oatmeal or oat cereal (1 c)        
Rice or rice cereal (1 c)        
Other grains (1 c)        
 
Eggs, Fish, Poultry & Meat   
(1 serving = 3 oz = 1 deck of cards) 
Eggs (1)        
Turkey or chicken         
Sausage (include Thanksgiving sausage)        
Pork        
Beef        
Lunch meat (also chopped ham)        
Did you eat the skin on your turkey or 
chicken? 
 No       Yes      Sometimes, not 
always    
 
 
 
 
 
Fruits (serving=1 item or 1 cup) 
Apples        
Oranges        
Banana        
Melons        
Other fruit        
 
 
Vegetables (serving=1 item or 1/2 c) 
Potatoes – fried (1 med)        
Potatoes – baked (1 med)        
Potatoes – boiled (1 med)        
Lettuce        
Tomatoes (1)        
Beans, green (1/2 c)        
Carrots, peas, corn        
Beets        
Squash        
Cauliflower & broccoli        
Cabbage (not sauerkraut)        
Other vegetables        
 
 
Sweets, Crackers, Pickles & Soups 
Cake or cookies (2)        
Pie (slice) (also kuchen&strudel)        
Candy (also chocolates, bars, 
hard candy, etc.) 
       
Crackers (2) (include saltines)        
Pickled foods (1 Tblsp) (ex. 
pickles, watermelon, tomatoes, 
corn relish) 
       
Sauerkraut        
Soup – milk- based broth        
Soup – clear broth        
 
 
Thinking about the meat you had today. 
About how many of these servings were 
fried? 
 All    Most    Some    None    Did not 
have any 
 
Did you eat anywhere not on the colony 
today?  
 Yes    No    If yes, 
describe__________________ 
 
Any other foods? 
_____________________________ 
___________________________________
________
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Day 3 
Mark how many servings of each of the following you ate. 
 
Dairy – include flavored milks  (serving = 1 
liquid cup or 1 slice or oz for cheeses) 
Milk – whole         
Milk – 2%         
Milk – 1% or skim        
Margarine or butter (pat)        
Yogurt, all kinds        
Cheese, all kinds         
Ice Cream or sherbert (1/2 c)        
 
Beverages (serving = 1 cup) 
Fruit juice (orange, grape, etc.)         
Vegetable juice (tomato, etc.)         
Wine or beer         
Coffee         
Tea         
Pop, kool-aid, or punch         
Pop, kool-aid, etc. DIET         
Water         
How many tsp of sugar do you put in your coffee  
and/or tea? _____ teaspoons 
 
 
Breads, Cereals & Grains 
Bread, wheat (1 slice)        
Bread, white (also biscuits, buns)        
Noodles, dumplings (also 
knödel, spätzel) (1/2 c) 
       
Maultauschen, cottage 
cheese pockets, etc. (1 item) 
       
Oatmeal or oat cereal (1 c)        
Rice or rice cereal (1 c)        
Other grains (1 c)        
 
Eggs, Fish, Poultry & Meat   
(1 serving = 3 oz = 1 deck of cards) 
Eggs (1)        
Turkey or chicken         
Sausage (include Thanksgiving sausage)        
Pork        
Beef        
Lunch meat (also chopped ham)        
 
Did you eat the skin on your turkey or 
chicken? 
 No       Yes      Sometimes, not 
always    
 
 
 
 
 
Fruits (serving=1 item or 1 cup) 
Apples        
Oranges        
Banana        
Melons        
Other fruit        
 
 
Vegetables (serving=1 item or 1/2 c) 
Potatoes – fried (1 med)        
Potatoes – baked (1 med)        
Potatoes – boiled (1 med)        
Lettuce        
Tomatoes (1)        
Beans, green (1/2 c)        
Carrots, peas, corn        
Beets        
Squash        
Cauliflower & broccoli        
Cabbage (not sauerkraut)        
Other vegetables        
 
 
Sweets, Crackers, Pickles & Soups 
Cake or cookies (2)        
Pie (slice) (also kuchen&strudel)        
Candy (also chocolates, bars, 
hard candy, etc.) 
       
Crackers (2) (include saltines)        
Pickled foods (1 Tblsp) (ex. 
pickles, watermelon, tomatoes, 
corn relish) 
       
Sauerkraut        
Soup – milk- based broth        
Soup – clear broth        
 
 
Thinking about the meat you had today. 
About how many of these servings were 
fried? 
 All    Most    Some    None    Did not 
have any 
 
Did you eat anywhere not on the colony 
today?  
 Yes    No    If yes, 
describe__________________ 
 
Any other foods? 
_____________________________ 
___________________________________
______ 
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